每周一次替西帕肽对比安慰剂在肥胖或超重且伴有体重相关合并症参与者中的疗效与安全性研究(SURMOUNT-1) (SURMOUNT-1)
Tirzepatide每周一次用于无2型糖尿病但患有肥胖或超重且伴有体重相关合并症参与者的疗效和安全性:一项随机、双盲、安慰剂对照试验(SURMOUNT-1)
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.
研究概览
详细说明
After screening, eligible participants are randomized in a 1:1:1:1 ratio to receive tirzepatide 5 mg, 10 mg, 15 mg, or placebo once weekly by subcutaneous injection using an autoinjector. All participants receive lifestyle counseling focused on a reduced-calorie diet and increased physical activity. The main treatment period is 72 weeks. Participants identified with prediabetes at randomization can continue study treatment for up to 176 weeks (plus follow-up), allowing evaluation of longer-term weight management and time to onset/progression to type 2 diabetes. Safety is monitored throughout, including adverse events and laboratory testing.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Seni S Lu, Phd
- 电话号码:+86 13076790030
- 邮箱:Seni-Lu@beijing-biotech.com
学习地点
-
-
Guangdong
-
Shenzhen、Guangdong、中国、518036
- 招聘中
- Peking University Shenzhen Hospital
-
接触:
- Zhen J Peng, Phd
- 电话号码:+86 13076790039
- 邮箱:Zhen-Peng@beijing-biotech.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- BMI ≥30 kg/m², OR BMI ≥27 kg/m² with ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
- History of at least one unsuccessful dietary effort to lose weight (self-reported)
- Investigator judges participant capable and willing to self-inject (or have assistance), follow lifestyle advice, maintain a diary, and complete questionnaires
- Age ≥18 years
- Meets protocol contraception/pregnancy criteria (as applicable) and provides written informed consent
Exclusion Criteria:
- Type 1 or type 2 diabetes, history of ketoacidosis/hyperosmolar state, or screening labs diagnostic of diabetes
- Recent significant weight change (>5 kg within 3 months prior to screening)
- Prior/planned bariatric surgery; recent/ongoing endoscopic or device-based obesity therapies
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Clinically significant gastric emptying abnormality or chronic use of drugs that directly affect GI motility
- History of chronic or acute pancreatitis
- Clinically significant thyroid abnormalities at screening (e.g., TSH outside protocol range) or anticipated need to initiate thyroid replacement during study
- Obesity due to other endocrinologic disorders (e.g., Cushing syndrome) or monogenic/syndromic obesity (e.g., MC4R deficiency, Prader-Willi syndrome)
- Significant unstable major depressive disorder/severe psychiatric disorder, lifetime suicide attempt, or concerning suicidality screening (PHQ-9/C-SSRS criteria)
- Uncontrolled hypertension; recent major cardiovascular events; NYHA class IV heart failure
- Active or significant liver disease or certain elevated liver tests at screening (per protocol thresholds)
- Elevated calcitonin above protocol thresholds; personal/family history of medullary thyroid carcinoma or MEN2
- Active/untreated malignancy or remission <5 years (with specified exceptions)
- Any other condition contraindicating GLP-1 receptor agonist therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:第一组:替泽帕肽 5 mg 每周一次 + 生活方式干预
|
(once-weekly SC injection; doses 5/10/15 mg) (once-weekly SC injection) increased physical activity counseling |
|
实验性的:第2组:替西帕肽10毫克每周一次+生活方式干预
|
(once-weekly SC injection; doses 5/10/15 mg) (once-weekly SC injection) increased physical activity counseling |
|
实验性的:Arm 3:替西帕肽 15 mg 每周一次 + 生活方式干预
|
(once-weekly SC injection; doses 5/10/15 mg) (once-weekly SC injection) increased physical activity counseling |
|
实验性的:第4组:每周一次安慰剂+生活方式干预
|
(once-weekly SC injection; doses 5/10/15 mg) (once-weekly SC injection) increased physical activity counseling |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
随机分组后体重平均百分比变化
大体时间:72周
|
72周
|
|
从随机化起体重减少≥5%的参与者百分比
大体时间:72周
|
72周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
甘油三酯中心血管代谢指标的变化
大体时间:72周
|
72周
|
|
|
Mean change in body weight
大体时间:72 Weeks
|
Mean change in body weight (kg) from randomization (pooled 10 mg and 15mg vs placebo) |
72 Weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- I8F-MC-GSHK(b)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.